New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

证券代码：300326 证券简称：ST 凯利 公告编号：2025-073 上海凯利泰医疗科技股份有限公司 关于公司回购专用证券账户库存股注销完成 暨股份变动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 上海凯利泰医疗科技股份有限公司（以下简称"公司"）对回购专用证券账 户中库存股予以注销，注销数量为13,651股，占公司总股本的0.0019%（按照公司 总股本717,026,333股计算）。本次注销完成后，公司股份总数由717,026,333股变 更为717,012,682股。 经中国证券登记结算有限责任公司深圳分公司确认，公司本次回购股份注销 手续已于2025年8月7日完成，公司总股本及无限售条件流通股股份数量发生变化， 现就本次回购股份注销完成暨股份变动情况公告如下： 一、公司回购股份及回购专用证券账户库存股注销已履行的相关审批程序 1、公司第三届董事会第二十六次会议、第三届董事会第二十七次会议分别 审议通过了《关于回购公司股份方案的议案》、《关于回购公司股份方案（调整 后）的议案》，同意使用公司自有资金或自筹资金以集中竞价交易方式回 ...

证券代码：300326 证券简称：ST 凯利 公告编号：2025-080 上海凯利泰医疗科技股份有限公司 关于涌金投资控股有限公司要约收购 公司股份的第三次提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 3.本次要约收购的申报代码：990084。 公司于2025年7月16日公告了《上海凯利泰医疗科技股份有限公司要约收购 报告书》（以下简称"要约收购报告书"）。涌金投资自2025年7月17日起以要 约方式收购公司部分股份。公司现就本次要约收购的有关情况作如下提示： 一、本次要约收购的基本情况 重要内容提示 1.本次公告为涌金投资控股有限公司（以下简称"收购人"或"涌金投资"） 以要约方式收购上海凯利泰医疗科技股份有限公司（以下简称"公司"或"上市 公司"）部分股份（以下简称"本次要约收购"）的第三次提示性公告。 2.本次要约收购期限为2025年7月17日至2025年8月15日。按照本次要约收购 申报程序，在本次要约收购期限内最后三个交易日（即2025年8月13日、2025年8 月14日和2025年8月15日），预受股东可撤回当日申报的预受要约，但不得 ...

Core Points - ST凯利 plans to distribute a bonus of 2.7 million yuan to its executives despite reporting a significant loss in 2024, which has raised concerns among some board members [3][4] - The company experienced a drastic decline in net profit, shifting from profit to a loss of 106 million yuan, a drop of 193.8% year-on-year [4] - The company has undergone two changes in chairmanship in 2025, indicating ongoing power struggles among major shareholders [6][7] Financial Performance - In 2024, ST凯利 achieved operating revenue of 985 million yuan, a year-on-year increase of 2.96%, but faced a net loss of 106 million yuan [4] - The decline in revenue was attributed to the impact of centralized procurement policies, affecting various business segments, including a 6.49% drop in revenue from its core vertebral minimally invasive business [4] - The company reported a gross margin of 55.40% for its vertebral business, down 5.26 percentage points from the previous year [4] Corporate Governance - The board's decision to award bonuses was passed with 5 votes in favor and 2 against, with dissenting board members citing the company's poor performance and lack of key performance indicators for bonus distribution [3][4] - The company has faced scrutiny from auditors, resulting in a qualified audit opinion and a warning on its stock due to internal control issues [5] - The ongoing power struggle among shareholders has led to significant changes in the board, with the second-largest shareholder,欣诚意, actively increasing its stake [8][9] Shareholder Activity -欣诚意 and the former chairman, 袁征, planned to increase their holdings by at least 10.36 million shares, representing 5.66% of the total shares before their recent purchases [8][9] -涌金投资 has proposed a tender offer to acquire 71.7 million shares at 5.18 yuan per share, which would increase its stake to 16.99% [10] - The competition for control has intensified, with multiple shareholders increasing their stakes and engaging in strategic maneuvers [12]

Group 1: New Stock Issuances - China Heavy Industry (601989) has a cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) has a buyback request period from August 13 to August 15, 2025[1] - Shenkai Co. (002633) has a tender offer period from July 29 to August 27, 2025[1] Group 2: Tender Offers and Mergers - ST Kelly (300326) has a tender offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) has a tender offer period from August 12 to September 10, 2025[1] - China Heavy Industry (601989) is involved in an absorption merger[1] Group 3: Abnormal Fluctuations - Tianlu Convertible Bond (110060) reported severe abnormal fluctuations on July 30, 2025[2] - Henghe Precision (300539) reported abnormal fluctuations on July 29, 2025[2] - ST Suwu (600200) reported abnormal fluctuations on August 6, 2025[2]

Core Viewpoint - ST凯利 is taking significant steps to enhance corporate governance and internal controls following an adverse audit report, indicating a commitment to compliance and risk management [2][3]. Group 1: Corporate Governance and Internal Controls - ST凯利's board has proposed to hold a temporary shareholders' meeting on August 28, 2025, to review key governance and internal control documents [2]. - The company is revising its foundational documents, including the Articles of Association and decision-making rules, to address compliance gaps and clarify responsibilities [2]. - A new anti-fraud and whistleblowing policy has been established to prevent operational risks, emphasizing accountability for violations [2][3]. Group 2: Risk Management and Accountability - To strengthen risk management, ST凯利 plans to purchase liability insurance for all directors and senior management, enhancing their protection while excluding coverage for regulatory penalties due to securities law violations [3]. - The audit committee has been authorized to conduct special audits on departing executives to reinforce accountability mechanisms [3]. Group 3: Management Changes and Business Strategy - ST凯利 intends to appoint 惠一微 as the new deputy general manager, marking a shift in management structure [3]. - The board has approved the sale of a 36.9% stake in 洁诺医疗, indicating a strategic move to divest non-core assets and focus on core areas such as orthopedic medical devices [3]. - The latest financial report shows that ST凯利 achieved a revenue of 265 million yuan in Q1 2025, a year-on-year increase of 7.56%, and a net profit of 21.76 million yuan, up 100.03% year-on-year [3].

聚焦于医药生物企业高度集中的上海地区，这一薪酬溢价效应更为突出。数据显示，纳入统计的39家上 海医药生物企业CFO薪酬总额4442.62万元，其平均年薪跃升至约113.91万元（中位数约102.20万元）。 相比全市场平均水平，上海医药生物CFO薪酬高出幅度达到39.8%（约32.43万元），凸显上海作为经济 中心的高昂运营成本和医药生物高附加值行业属性所带来的强力人才溢价。 在此背景下，ST凯利财务总监李元平2024年139.59万元的薪酬上榜前十备受关注。 专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 | | | | 2024年医药生物行业的上海地区上市公司CFO薪酬前十 | | | | | --- | --- | --- | --- | --- | --- | --- | ...

Group 1: Agricultural Products - Company received approval from the China Securities Regulatory Commission for a stock issuance to specific targets, valid for 12 months from the date of approval [1] Group 2: Shareholder Reductions - Guangdong Science and Technology Venture Investment Co., Ltd. plans to reduce its stake in Hongqiang Co. by up to 211.6 million shares, representing 1% of total shares [1] - Huizhou Junqiang Equity Investment Partnership plans to reduce its stake in Green Precision by up to 123.8 million shares, representing 0.2995% of total shares [2] - Philips (China) Investment Co., Ltd. plans to reduce its stake in Chuangye Huikang by up to 46.33 million shares, representing 3% of total shares [2] - Chengdu Dijing Financial Consulting Center and Zhuo Yuqing plan to reduce their stake in Ruidi Zhichu by up to 194.65 million shares, representing 2.52% of total shares [4] - Ruizhong Life Insurance Co. plans to reduce its stake in Tongzhou Electronics by up to 752.44 million shares, representing 1% of total shares [5] - Zhejiang Taian Tai Investment Consulting Partnership plans to reduce its stake in Zhejiang Agricultural Shares by up to 15.2853 million shares, representing 3% of total shares [13] - Company executives plan to reduce their stake in Zhimi Intelligent by up to 47,000 shares, representing 0.0187% of total shares [18] Group 3: Financial Transactions - Shenzhen Metro Group will provide Vanke A with a loan of up to 1.681 billion yuan for debt repayment, with a term of no more than 3 years and an interest rate of 2.34% [6] - Sichuan Road and Bridge received a commitment letter for a stock repurchase loan of up to 180 million yuan from China Minsheng Bank, with a term of no more than 3 years [8] Group 4: Company Developments - Xiangyuan Cultural Tourism plans to upgrade the Danxia Mountain scenic area with a budget of approximately 26.8511 million yuan [7] - ST Kelly plans to sell a 36.9% stake in Jieno Medical and exit its investment in Jingzheng Medical [10] - Yifan Pharmaceutical's subsidiary's application for the registration of melatonin granules has been accepted by the National Medical Products Administration [12] - Aishide plans to acquire a 13.6365% stake in Gongqingcheng Aishide Innovation for approximately 1.0157 billion yuan [20] - Roman Co. intends to acquire a 39.23% stake in Wutong High-Tech, becoming its largest shareholder [22]

来源：证券时报网 作者：唐强 ST凯利拟为高管发放2024年度奖金270万元，两名董事投票反对："当年度利润同比大降"。 8月5日晚间，ST凯利(300326)发布公告，该上市公司已于8月4日召开董事会，审议了《关于聘任惠一微 先生为副总经理的议案》、《关于高级管理人员2024年度奖金的议案》等16项议案，并提请于8月28日 召开2025年第二次临时股东大会，由股东审议表决相关议案。 需要指出的是，经提名，ST凯利此次董事会同意聘任惠一微为上市公司副总经理，任期自董事会审议 通过之日起至第六届董事会任期届满为止。根据公司相关制度，结合ST凯利经营规模等实际情况并参 照行业薪酬水平，惠一微担任副总经理后，上市公司拟向其发放2025年度固定薪酬54万元/年（含 税），发放办法为按月发放。 针对该人事聘任议案，ST凯利董事会表决结果为，本议案4票同意、0票反对、2票弃权、1票回避获得 通过。 另外，ST凯利董事会审议通过了《关于高级管理人员2024年度奖金的议案》，为了鼓励上市公司高级 管理人员在过去一年来努力为公司创造利润与未来发展规划所做出的贡献，本着责任权利相结合的原 则，结合国家有关的法律、法规、公司章程， ...

Core Viewpoint - ST凯利 plans to issue a total of 2.7 million yuan in bonuses for its senior management for the year 2024, despite significant declines in profits compared to the previous year, leading to opposition from two board members [1][2]. Group 1: Bonus Proposal - The board of ST凯利 approved a proposal to grant 2.7 million yuan in bonuses to senior management for 2024, based on their contributions to profit generation and future planning [2]. - The proposal received 5 votes in favor and 2 against, with board members 金诗强 and 狄朝平 opposing the decision due to the company's poor financial performance [2]. Group 2: Financial Performance - In 2024, ST凯利 reported a revenue of 985 million yuan, a year-on-year increase of 2.96%, but experienced a significant decline in operating profit and total profit, with losses of 107 million yuan and 110 million yuan, respectively, representing year-on-year decreases of 176.39% and 182.63% [3]. - The net profit attributable to shareholders was -106 million yuan, with a non-recurring net profit of -65.31 million yuan, reflecting year-on-year declines of 193.80% and 205.93% [3]. Group 3: Corporate Actions - ST凯利 announced plans to sell a 36.9% stake in 洁诺医疗 to 上海荟添医疗科技有限公司, as part of a strategy to exit its investment in 景正医疗 [3]. - 洁诺医疗 reported revenues of 282 million yuan and 126 million yuan for 2024 and January-May 2025, respectively, with net profits of 16.98 million yuan and 15.22 million yuan [3]. - The valuation of 洁诺医疗's total equity was assessed at 425 million yuan, with an increase of 299 million yuan, resulting in a growth rate of 237.24% [3].